Codexis discovers, develops and sells enzymes and other proteins to its clients. Co.'s business segments are: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications; and Novel Biotherapeutics, which discovers, improves, and/or develops biotherapeutic drug candidates, including CDX-6114 for the potential treatment of hyperphenylalaninemia. Co.'s products include biocatalysts, chemical intermediates and Codex® biocatalyst panels and kits. The CDXS YTD return is shown above.
The YTD Return on the CDXS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CDXS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CDXS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|